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This study investigated Staphylococcus aureus carriage in patients with microbial keratitis (MK). 215 
patients with MK, 60 healthy controls and 35 patients with rheumatoid arthritis (RA) were included. 
Corneal scrapes were collected from patients with MK. Conjunctival, nasal and throat swabs were 
collected from the non-MK groups on a single occasion and from the MK group at presentation and 
then at 6 and 12 weeks. Samples were processed using conventional diagnostic culture. 68 (31.6%) 
episodes of clinically suspected MK were classed as recurrent. Patients with recurrent MK had a higher 
isolation rate of S. aureus from their cornea than those with a single episode (p < 0.01) and a higher 
isolation rate of S. aureus from their conjunctiva compared to control participants, 20.6% (14/68) 
versus 3% (5/60) respectively (p = 0.01). Significantly more patients with recurrent MK (12/68, 17.6%) 
were found to have S. aureus isolated from both their conjunctiva and nose than those with a single 
episode of MK (7/147, 4.8% p = 0.002) and compared to patients in the control group (3/60, 5.0% 
p = 0.03). The results indicate that patients with recurrent MK have higher rates of carriage of S. aureus 
suggesting endogenous site colonisation as a possible source of recurrent infection. 
Microbial keratitis (MK) is a major cause of loss of vision worldwide with each episode leading to further corneal 
scarring and visual  impairment1–3. Treatment involves managing any other associated ocular surface disease 
involvement, removing any known risk factors such as contact lens wear and aggressive topical antimicrobial 
therapy. The patient requires close treatment response monitoring, often including hospitalisation followed by 
frequent outpatient visits. The risk of developing MK and the severity of the disease depend on both the identity 
of the infecting organism and the condition of the ocular  surface4. We recently carried out a retrospective case 
series that included 2418 patients with clinically suspected MK over a 16-year period. Twelve percent of patients 
were found to have at least two episodes, 3.68% at least three, 1.65% at least four and 0.91% five or more episodes. 
In patients who had recurrent episodes of MK, Staphylococcus aureus was isolated significantly more frequently 
than other pathogenic bacteria, possibly suggesting an endogenous source for the recurrent nature of S. aureus 
related  MK5. S. aureus, is considered a pathogen in ocular surface infections in contrast to coagulase negative 
staphylococci (CNS), the predominant isolate cultured from healthy  eyes6,7.
S. aureus is a major human pathogen that can cause wound infections, bacteraemia and sepsis associated 
with a high mortality rate. The bacterium is a commensal of the moist squamous epithelium of the anterior 
nares with persistent carriage in 20% of the healthy human  population8. A higher prevalence of S. aureus nasal 
colonisation has been found in patients with autoimmune diseases such as rheumatoid arthritis (RA) then in the 
general  population9,10. Previous studies have also revealed that nasal carriers are at increased risk of acquiring S. 
aureus related  infections8. Many host and bacterial determinants for nasal carriage are defined but the underlying 
processes of how carriage is established and maintained are largely  undefined11.
A key feature of non-ocular S. aureus infection is its recurrence, which is seen in approximately 30% of all 
 cases12,13. While recurrent or persistent carriage might predispose individuals to recurrent S. aureus keratitis, 
especially those with underlying ocular surface disease this link has yet to be demonstrated. Identification of 
endogenous host sites such as the conjunctiva, nose and throat are of particular importance for developing 
interventions to prevent further episodes of MK and subsequent vision loss, particularly since the emergence 
of methicillin-resistant Staphylococcus aureus (MRSA). We therefore, investigated S. aureus carriage in the con-
junctiva, nose or throat in patients with single episode and recurrent MK in comparison to control groups.
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Results
In total, 215 patients with clinically suspected MK, 60 healthy controls and 35 patients with RA were included. 
68 (31.6%) episodes of clinically suspected MK were recurrent within the study period. Baseline characteristics 
demographics and predisposing risk factors of the 215 patients with clinically suspected MK are presented in 
Table 1. Patients with recurrent MK had higher rates of risk factors such as RA, Sjogren’s syndrome, ectodermal 
dysplasia and ocular surface disease and were more likely to be on systemic immunosuppression (Table 1). 
Conversely, patients with single episode MK had higher rates of exogenous risk factors such as contact lens wear 
and corneal trauma (Table 1).
Corneal scrapes were obtained in 204/215 patients. The corneal scrape isolation rate was 25.5% (52/204). 
A topical antimicrobial had been used immediately prior to presentation in 83 (26.3%) of clinically suspected 
MK patients. The corneal scrape isolation rate was no different for patients who had or had not received an 
antimicrobial (21/80 (26.3%) and 31/124 (25.0%) (p = 0.84), respectively. The microbial isolates are shown in 
Table 2. Although there was no significant difference in the corneal scrape isolation rate between those that had 
recurrent MK and those who presented with a single episode (p = 0.53), recurrent MK patients were found to 
have significantly higher corneal scrape isolations of S. aureus than those MK patients presenting with a single 
episode, that is, 5/13 (38.5%) of positive scrapes in the recurrent MK group versus 2/39 (5.1%) positive scrapes 
in the single episode MK group (p = 0.001). Higher levels of Gram-negative bacilli, particularly Pseudomonas 
species were found in the single episode MK group, 12.9% versus 4.4% respectively (p = 0.055).
Conjunctival, nasal and throat S. aureus carriage. Patients with recurrent MK were found to have a 
significantly higher isolation rate of S. aureus from their conjunctiva on presentation compared to control par-
ticipants, 20.6% (14/68) versus 3% (5/60) respectively (p = 0.01), Table 3. No difference was found between the 
isolation rates of S. aureus from the conjunctiva of patients with non-recurrent MK on presentation compared to 
control participants (p = 0.77). Isolation rates of S. aureus from the nose and throat were not found to be signifi-
cantly higher in either the single or recurrent MK patient groups compared to controls, Table 3.
Significantly more patients in the recurrent MK group were found to have S. aureus isolated from both their 
conjunctiva and nose than patients in the single episode MK group, 12/68 (17.6%) versus 7/147 (4.8%) (p = 0.002) 
respectively and compared to patients in the control group (3/60, 5.0% p = 0.03).
Conjunctival, nose and throat carriage of S. aureus was seen to significantly decline over the 3 visits only in 
the recurrent, clinically suspected bacterial keratitis group (Table 4). Of the 7 MK patients who had S. aureus 
isolated from their corneal scrape, 2 participants consistently had S. aureus isolated from their conjunctiva at 
all three visits.
There was no difference in the isolation rate of S. aureus from the conjunctiva, nares and throat in patients 
who had or had not received an antimicrobial: 8/83 (9.6%) and 15/132 (11.4%) (p = 0.69); 29/83 (34.9%) and 
47/132 (35.6%) (p = 0.92) and 11/83 (13.3%) and 18/132 (13.6%) (p = 0.94)), respectively.
Comparison between patients with RA and healthy controls. Twenty-nine of the 35 patients with 
RA were on systemic immunotherapy which included monotherapy or dual therapy with methotrexate (21), 
etanercept (3) and prednisolone (7). There was no statistically significant difference in the isolation rates of S. 
aureus from the conjunctiva, nose and throat between healthy controls and patients with RA (whether or not on 
systemic immunotherapy), Table 5. There was a non-significant trend (p = 0.06) for patients with RA on systemic 
immunotherapy to have more S. aureus nasal carriage then those patients with RA not on systemic immuno-
therapy, 13/29 (44.8%) versus 0 respectively, (Table 5).
Table 1.  Baseline demographics and predisposing risk factors of patients with clinically suspected MK. MK 
microbial keratitis. *Significant after Bonferroni correction.
Single episode MK (n = 147) Recurrent MK (n = 68) P-value
Age (median, IQR) 48 years (30.5) 54 years (19.3) 0.21
Males 79 (53.7%) 30 (44.1%) 0.19
Systemic risk factors
Diabetes mellitus 10 (6.8%) 6 (8.8%) 0.60
Rheumatoid arthritis 6 (4.1%) 16 (23.5%)  < 0.01*
Sjogren’s syndrome 1 (0.7%) 6 (8.8%) 0.004*
Ectodermal dysplasia 0 4 (5.9%) 0.009*
Systemic immunosuppression 5 (3.4%) 13 (19.1%)  < 0.001*
Ocular risk factors
Contact lens wear 61 (42.5%) 7 (10.3%)  < 0.001*
Ocular surface disease 64 (43.5%) 46 (67.6%) 0.001*
Corneal trauma 20 (13.6%) 2 (2.9%) 0.02
Topical steroid prior to presentation 12 (8.2%) 12 (17.6%) 0.06
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Table 2.  Isolates from cases of presumed microbial keratitis grouped according to patients with recurrent 
episodes and those presenting with only a single episode. *The total number of isolates do not add up to 39 and 
13 respectively because one recurrent patient had mixed infection with S. aureus, E.coli and S. pneumoniae and 
two single episode patients had mixed infection with Enterobacteriaeceae and Alpha-Haemolytic Streptococci, 
and Pseudomonas aeruginosa and Aspergillus sp, respectively. MK microbial keratitis, CNS coagulase-negative 
Staphylococci.
Single episode MK (n = 146) Recurrent MK (n = 58)
Total number of positive samples 39* (26.7%) 13* (22.4%)
Gram-positive cocci 19 (13.0%) 10 (17.2%)
S. aureus 2 (1.4%) 5 (8.6%)
CNS 11 (7.5%) 3 (5.2%)
S. pneumoniae 4 (2.7%) 2 (3.4%)
Alpha-haemolytic streptococci 2 (1.4%) 1 (1.7%)
Gram-positive bacilli 1 (0.7%) 1 (1.7%)
Bacillus sp. 0 1 (1.7%)
Diptheroids 1 (0.7%) 0
Gram-negative bacilli 19 (13.0%) 3 (5.2%)
Pseudomonas aeruginosa 9 (6.1%) 1 (1.7%)
Moraxella sp. 4 (2.7%) 0
Kingella 1 (0.7%) 0
Proteus 0 1 (1.7%)
Citrobacter koseri 1 (0.7%) 0
Acinetobacter lwoffii 1 (0.7%) 0
Serratia marcescens 1 (0.7%) 0
E.coli 1 (0.7%) 1 (1.7%)
Other Enterobacteriaceae sp. 1 (0.7%) 0
Protozoa 1 (0.7%) 0
Acanthamoeba sp. 1 (0.7%) 0
Fungi 1 (0.7%) 0
Aspergillus sp. 1 (0.7%) 0
Table 3.  Numbers of individuals in each group who had S. aureus isolated from their conjunctiva, nose and 
throat on presentation. P-values represent comparisons of each group to the control group. MK microbial 
keratitis.
Control (n = 60)
Single episode MK 
(n = 147) Recurrent MK (n = 68)
MK with positive 
scrape (n = 52)
Conjunctiva 3 (5.0%) 9 (6.1%) P = 1.00 14 (20.6%) P = 0.02 6 (11.5%) P = 0.30
Nose 18 (30.0%) 47 (32.0%) P = 0.66 29 (42.6%) P = 0.12 17 (32.7%) P = 0.66
Throat 4 (6.8%) 19 (12.9%) P = 0.33 10 (14.7%) P = 0.26 9 (17.3%) P = 0.14
Table 4.  Microbial keratitis participants overall S. aureus carriage (total S. aureus conjunctival, nasal and 
throat carriage) at presentation (visit 1), 6 weeks post presentation (visit 2) and 12 weeks post presentation 
(visit 3). Values represent the total number of swabs obtained (nasal swabs were classified as one value and 
counted as positive regardless if one or both nares were positive). P-values calculated using repeated measures 
logistic regression (Wald Chi-Square) and represent change over time in S. aureus colonization prevalence for 
each of the four subject groups. MK microbial keratitis.
Single episode MK Recurrent MK MK positive scrape episodes S. aureus MK episodes
Visit 1 75/441 (17.0%) 53/204 (26.0%) 32/156 (20.5%) 6/21 (28.6%)
Visit 2 47/303 (15.5%) 26/168 (15.5%) 26/117 (22.2%) 5/18 (27.8%)
Visit 3 40/237 (16.9%) 26/141 (18.4%) 17/96 (17.7%) 4/12 (33.3%)
P value 0.85 0.04 0.72 0.94
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Discussion
Recurrent MK is common but little attention has been paid to potential reservoirs of infection and optimal man-
agement. This study is the first prospective study to establish a potential source of recurrent MK by comparing 
multiple endogenous site testing between MK patients and healthy controls over time. Similar to a previous study 
we found S. aureus to be the most frequently associated organism in recurrent  MK5. We found that S. aureus 
was present in the conjunctiva significantly more frequently in patients who had recurrent MK compared to 
healthy controls or patients with RA. In addition, patients who had recurrent episodes of MK were found to have 
significantly more concurrent S. aureus conjunctiva and nasal carriage than patients who had single episode and 
also in comparison to patients in the healthy control group. This would suggest that the conjunctiva and nose 
and possibly other unidentified sites such as the lid margin may be endogenous sources of S. aureus in patients 
with recurrent MK.
The pathogenicity of S. aureus is mediated by a multitude of factors including bacterial surface adhesins, 
immune evasive proteins and toxins including alpha-, beta- and gamma-toxin plus several leukocidins that medi-
ate tissue damage and contribute towards the induction of the inflammatory  response15–18. Modern molecular 
diagnostic tools such as PCR and genome sequencing have provided a better understanding of the composition 
of the ocular surface microbiome and how this changes with conditions such as: contact lens  wear19, antibiotic 
 exposure20, infectious  states21, atopic and dry eye  disease22–25 as well as the effects of age and  gender26. Presence 
of S. aureus on the ocular surface has been associated with dry eye and  atopia22–25 which are both known risk 
factors for MK. In this study, we have demonstrated that patients with recurrent MK are more likely to have 
endogenous risk factors such as RA, Sjogren’s syndrome, ectodermal dyplasia, ocular surface disease and are 
more likely to be on systemic immunosuppression. These conditions may predispose to an increased risk of 
ocular surface S. aureus  colonisation27.
Patients with RA with corneal ulceration have an increased risk of mortality and eye morbidity from infection 
and a much poorer prognosis than patients with RA without corneal ulceration, and infection is a significant risk 
 factor14. Although we did not find a significant difference in S. aureus nasal carriage in patients with RA between 
those with or without systemic immunotherapy, this may reflect that only 6 of the 35 patients with RA were not 
on immunotherapy. This trend would be consistent with Goodman et al., who found that patients with RA on 
biological drugs, such as etanercept in our study group, had a higher prevalence of S. aureus colonisation (37%) 
compared to those with RA on disease-modifying anti-rheumatic drugs (DMARDs) alone (24%) or control 
subjects affected by osteoarthritis (20%)27.
We identified no significant difference in S. aureus nasal and throat colonisation between patients with a 
single episode and recurrent keratitis and healthy controls, although it is possible that our sample size was too 
small to detect a difference between these groups for S. aureus nasal and throat carriage. In particular, one of 
the limitations of this study was the low isolation rate from corneal scrapes and it is therefore possible that other 
bacteria from the conjunctiva and nose were associated with MK.
In this study we identified an increased isolation of S. aureus from endogenous sites in patients with recurrent 
MK compared to patients with a single episode of MK and this highlights the importance of collecting samples 
from the conjunctiva and nose in patients with recurrent keratitis. With the use of modern molecular diagnostic 
tools, it would be useful to examine whether the strains of S. aureus obtained from endogenous sites such as 
the conjunctiva, nose and skin are the same as those obtained from the corneal ulcer and whether patients with 
recurrent MK are persistently infected with the same strain of S. aureus or have intermittent carriage of different 
strains. A study in which volunteers were artificially inoculated nasally with a mixture of S. aureus strains showed 
that non carriers quickly eliminated the inoculated S. aureus strains whereas most persistent carriers selected 
their original resident S. aureus strain from the inoculation  mixture28. The authors concluded that host charac-
teristics substantially determine the S. aureus nasal carrier state and it this therefore likely that a similar process 
occurs in the conjunctiva. Collecting isolates from patients with recurrent MK and resolving their relatedness 
(comparative genomics) between episodes would enable the development of decolonisation strategies to reduce 
the risk of recurrent infection related visual loss.
Methods
All included patients provided informed consent. The study received prospective ethical approval from the 
Northwest NHS Research Ethics Committee and was conducted according to the ethical standards set out in 
the 1964 Declaration of Helsinki, as revised in 2000.
Table 5.  Numbers of individuals in the healthy control group versus patients with RA on systemic 
immunotherapy and patients with RA not on systemic immunotherapy who had S. aureus isolated from 
their conjunctiva, nose and throat. a P-values represent comparison between patients with RA on systemic 
immunotherapy and healthy controls. b P-values represent comparison between patients with RA not on 
systemic immunotherapy and healthy controls. RA rheumatoid arthritis.
Healthy controls 
(n = 60)
Patients with RA on 
systemic immunotherapy 
(n = 29)





Conjunctiva 3 (5.0%) 0 P = 0.55a 0 P = 1.00b –
Nose 18 (30.0%) 13 (44.8%) P = 0.17a 0 P = 0.18b P = 0.06
Throat 4 (6.8%) 3 (10.3%) P = 0.68a 0 P = 1.00b P = 1.00
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Consecutive patients presenting with suspected MK between January 2011 and November 2012 at The Royal 
Liverpool University Hospital were recruited and followed up at 6 and 12 weeks. Demographical and clinical 
information were collected through patient interview and medical notes review. Corneal scrapes were collected 
from the corneal ulcer at presentation. At presentation and at each subsequent visit conjunctival swabs from 
each eye, a nasal swab from each nostril and a throat swab were collected. All patients received a topical fluoro-
quinolone as initial treatment.
A recurrent episode was defined as a prior or further episode of clinically suspected MK occurring in the 
same patient (in either eye) either more than 3 months before or after the index episode or within 3 months of 
the index episode if there was documentation that the corneal ulcer had healed in the interim.
In addition to patients with MK, patients with no previous history of MK and current eye drop use, and 
patients with no previous history of MK and eye drop use but a history of RA, were recruited to a healthy control 
group and a RA group. These patients were recruited from patients attending for routine cataract surgery and 
from those attending a RA clinic. Conjunctival, nasal and throat swabs were collected from both the healthy 
and RA group on a single occasion.
Sampling and microbial processing. Corneal samples were taken by scraping the edges of the ulcer with 
a number 11 blade (Swann Morton, Sheffield, UK) whilst wearing sterile gloves, as previously  described29,30. The 
blade was placed into enrichment culture broth (brain heart infusion, BHI) and transported to the microbiology 
laboratory at room  temperature29. Conventional diagnostic culture was carried out as previously  described30. 
Briefly, BHI bottles were vortexed for 5–10  s and 10 μl aliquots inoculated onto blood, chocolate, fastidious 
anaerobic and Sabouraud’s dextrose agar plates and Robertson’s cooked meat enrichment broth (Oxoid, Bas-
ingstoke, UK). For Acanthamoeba spp. culture, 20 μl of BHI was inoculated onto a non-nutrient agar (Oxoid) 
seeded with Escherichia coli. All plates were incubated overnight at 37  °C under both aerobic and enriched 
carbon dioxide (5%) atmospheric conditions. Agar plates and a 24 h subculture of the BHI broth in enrichment 
medium were examined for evidence of bacterial growth after 24 and 48 h incubation. All isolates were identi-
fied using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (Bruker, Bremen, Ger-
many). Acanthamoeba plates were examined daily for 7 days for the characteristic appearances of acanthamoeba 
trophozoites and  cysts30.
Conjunctival, nasal and oral swabs were inoculated onto blood, chocolate, fastidious anaerobic and Sab-
ouraud’s dextrose agar plates (Oxoid, Basingstoke, UK) and processed as above.
Statistical analysis. All data collected in the study were entered into an electronic database via Microsoft 
Excel 2016 and analysed using SPSS (version 26). The independent T-test was used to assess differences for 
normally distributed continuous variables and the χ2 was used as indicated for the analysis of categorical vari-
ables where the number of observations was 5 or larger. For small-sized samples (fewer than five observations), 
Fisher’s exact test was used. Repeated measures logistic regression was used to analyse the difference between 
swab results over the 3 visits.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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